Cardiovascular mortality and morbidity burden in successive and age pre-stratified case-control cohorts of breast cancer women. A population-based study.
Lidia StaszewskyFabio RobustoVito LeporeLucia BiscegliaVito PetraroloAntonio D'EttorreGianni TognoniRoberto LatiniPublished in: Breast cancer research and treatment (2020)
The incidence of CV causes of death 3 and 5 years after BC diagnosis was very low, even if an excess in risk of death for HF as compared with the control cohort was observed. While younger patients seems to tolerate BC and BC therapy better in the short term, HF mortality and morbidity resulted significantly increased at 5-year follow-up. As the risk for hospitalization for CV reasons increased at 5-year follow-up in particular in women aged less than 50 years, CV monitoring in this subgroup of patients seems mandatory.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- risk factors
- prognostic factors
- randomized controlled trial
- cardiovascular disease
- case control
- cardiovascular events
- pregnant women
- metabolic syndrome
- adipose tissue
- stem cells
- patient reported outcomes
- mesenchymal stem cells
- skeletal muscle
- atrial fibrillation
- breast cancer risk
- cervical cancer screening